Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at the 2022 CDKL5 Forum Hosted by the Loulou Foundation

CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning to identify and validate drug targets and therapeutic candidates. Today, Vyant Bio provided key takeaways from its Platform and Poster presentations delivered by Matthew Green, Ph.D., Vyant Bio’s Senior Scientist, at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7^th and 8^th, 2022, in Boston, MA. CDKL5 (cyclin-dependent kinase-like 5) deficiency disorder (CDD) is a rare neurodevelopmental condition caused by pathogenic mutations in the CDKL5 gene. The most common symptoms include early-onset, difficult to control seizures and neurodevelopmental impairment that affects cognitive, motor, speech and visual function.

Read more at globenewswire.com